Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone Combined with Clozapine in Schizophrenia
NCT06906224Phase 1Completed
- Start
- May 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of buspirone in schizophrenia (3 arms). Primary endpoints: Positive and Negative Syndrome Scale at 12 weeks, Repeatable Battery for the Assessment of Neuropsychological Status at 12 weeks and 1 more. Started May 2022; status: completed.
02
Drugs
buspirone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06906224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06906224.